Research ArticleArticle
Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study
Arto V. Heinonen, Kalle J. Aaltonen, Jaana T. Joensuu, Jukka P. Lähteenmäki, Marja I. Pertovaara, Matti K. Romu, Hanna E. Hirvonen, Aki K. Similä, Marja L. Blom and Dan C. Nordström
The Journal of Rheumatology October 2015, jrheum.150389; DOI: https://doi.org/10.3899/jrheum.150389
Arto V. Heinonen
From the University of Helsinki, Helsinki; North Carelia Central Hospital, Joensuu; Tampere University Hospital, Tampere; Helsinki University Central Hospital, Helsinki; Turku City Hospital, Turku, Finland. Study partially funded by Pfizer. A.V. Heinonen, BSc(pharm), University of Helsinki; K.J. Aaltonen, PhD (pharm), University of Helsinki; J.T. Joensuu, MSc(pharm), University of Helsinki; J.P. Lähteenmäki, MD, North Carelia Central Hospital; M.I. Pertovaara, MD, PhD, Tampere University Hospital; M.K. Romu, MD, Helsinki University Central Hospital; H.E. Hirvonen, MD, Helsinki University Central Hospital; A.K. Similä, MD, Turku City Hospital; M.L. Blom, PhD, Professor, University of Helsinki; DC Nordström, MD, PhD, Adj. Professor, University of Helsinki, and Helsinki University Central Hospital. Address correspondence to A.V. Heinonen, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland. E-mail: arto.heinonen@helsinki.fi. Accepted for publication August 5, 2015.
Kalle J. Aaltonen
From the University of Helsinki, Helsinki; North Carelia Central Hospital, Joensuu; Tampere University Hospital, Tampere; Helsinki University Central Hospital, Helsinki; Turku City Hospital, Turku, Finland. Study partially funded by Pfizer. A.V. Heinonen, BSc(pharm), University of Helsinki; K.J. Aaltonen, PhD (pharm), University of Helsinki; J.T. Joensuu, MSc(pharm), University of Helsinki; J.P. Lähteenmäki, MD, North Carelia Central Hospital; M.I. Pertovaara, MD, PhD, Tampere University Hospital; M.K. Romu, MD, Helsinki University Central Hospital; H.E. Hirvonen, MD, Helsinki University Central Hospital; A.K. Similä, MD, Turku City Hospital; M.L. Blom, PhD, Professor, University of Helsinki; DC Nordström, MD, PhD, Adj. Professor, University of Helsinki, and Helsinki University Central Hospital. Address correspondence to A.V. Heinonen, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland. E-mail: arto.heinonen@helsinki.fi. Accepted for publication August 5, 2015.
Jaana T. Joensuu
From the University of Helsinki, Helsinki; North Carelia Central Hospital, Joensuu; Tampere University Hospital, Tampere; Helsinki University Central Hospital, Helsinki; Turku City Hospital, Turku, Finland. Study partially funded by Pfizer. A.V. Heinonen, BSc(pharm), University of Helsinki; K.J. Aaltonen, PhD (pharm), University of Helsinki; J.T. Joensuu, MSc(pharm), University of Helsinki; J.P. Lähteenmäki, MD, North Carelia Central Hospital; M.I. Pertovaara, MD, PhD, Tampere University Hospital; M.K. Romu, MD, Helsinki University Central Hospital; H.E. Hirvonen, MD, Helsinki University Central Hospital; A.K. Similä, MD, Turku City Hospital; M.L. Blom, PhD, Professor, University of Helsinki; DC Nordström, MD, PhD, Adj. Professor, University of Helsinki, and Helsinki University Central Hospital. Address correspondence to A.V. Heinonen, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland. E-mail: arto.heinonen@helsinki.fi. Accepted for publication August 5, 2015.
Jukka P. Lähteenmäki
From the University of Helsinki, Helsinki; North Carelia Central Hospital, Joensuu; Tampere University Hospital, Tampere; Helsinki University Central Hospital, Helsinki; Turku City Hospital, Turku, Finland. Study partially funded by Pfizer. A.V. Heinonen, BSc(pharm), University of Helsinki; K.J. Aaltonen, PhD (pharm), University of Helsinki; J.T. Joensuu, MSc(pharm), University of Helsinki; J.P. Lähteenmäki, MD, North Carelia Central Hospital; M.I. Pertovaara, MD, PhD, Tampere University Hospital; M.K. Romu, MD, Helsinki University Central Hospital; H.E. Hirvonen, MD, Helsinki University Central Hospital; A.K. Similä, MD, Turku City Hospital; M.L. Blom, PhD, Professor, University of Helsinki; DC Nordström, MD, PhD, Adj. Professor, University of Helsinki, and Helsinki University Central Hospital. Address correspondence to A.V. Heinonen, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland. E-mail: arto.heinonen@helsinki.fi. Accepted for publication August 5, 2015.
Marja I. Pertovaara
From the University of Helsinki, Helsinki; North Carelia Central Hospital, Joensuu; Tampere University Hospital, Tampere; Helsinki University Central Hospital, Helsinki; Turku City Hospital, Turku, Finland. Study partially funded by Pfizer. A.V. Heinonen, BSc(pharm), University of Helsinki; K.J. Aaltonen, PhD (pharm), University of Helsinki; J.T. Joensuu, MSc(pharm), University of Helsinki; J.P. Lähteenmäki, MD, North Carelia Central Hospital; M.I. Pertovaara, MD, PhD, Tampere University Hospital; M.K. Romu, MD, Helsinki University Central Hospital; H.E. Hirvonen, MD, Helsinki University Central Hospital; A.K. Similä, MD, Turku City Hospital; M.L. Blom, PhD, Professor, University of Helsinki; DC Nordström, MD, PhD, Adj. Professor, University of Helsinki, and Helsinki University Central Hospital. Address correspondence to A.V. Heinonen, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland. E-mail: arto.heinonen@helsinki.fi. Accepted for publication August 5, 2015.
Matti K. Romu
From the University of Helsinki, Helsinki; North Carelia Central Hospital, Joensuu; Tampere University Hospital, Tampere; Helsinki University Central Hospital, Helsinki; Turku City Hospital, Turku, Finland. Study partially funded by Pfizer. A.V. Heinonen, BSc(pharm), University of Helsinki; K.J. Aaltonen, PhD (pharm), University of Helsinki; J.T. Joensuu, MSc(pharm), University of Helsinki; J.P. Lähteenmäki, MD, North Carelia Central Hospital; M.I. Pertovaara, MD, PhD, Tampere University Hospital; M.K. Romu, MD, Helsinki University Central Hospital; H.E. Hirvonen, MD, Helsinki University Central Hospital; A.K. Similä, MD, Turku City Hospital; M.L. Blom, PhD, Professor, University of Helsinki; DC Nordström, MD, PhD, Adj. Professor, University of Helsinki, and Helsinki University Central Hospital. Address correspondence to A.V. Heinonen, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland. E-mail: arto.heinonen@helsinki.fi. Accepted for publication August 5, 2015.
Hanna E. Hirvonen
From the University of Helsinki, Helsinki; North Carelia Central Hospital, Joensuu; Tampere University Hospital, Tampere; Helsinki University Central Hospital, Helsinki; Turku City Hospital, Turku, Finland. Study partially funded by Pfizer. A.V. Heinonen, BSc(pharm), University of Helsinki; K.J. Aaltonen, PhD (pharm), University of Helsinki; J.T. Joensuu, MSc(pharm), University of Helsinki; J.P. Lähteenmäki, MD, North Carelia Central Hospital; M.I. Pertovaara, MD, PhD, Tampere University Hospital; M.K. Romu, MD, Helsinki University Central Hospital; H.E. Hirvonen, MD, Helsinki University Central Hospital; A.K. Similä, MD, Turku City Hospital; M.L. Blom, PhD, Professor, University of Helsinki; DC Nordström, MD, PhD, Adj. Professor, University of Helsinki, and Helsinki University Central Hospital. Address correspondence to A.V. Heinonen, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland. E-mail: arto.heinonen@helsinki.fi. Accepted for publication August 5, 2015.
Aki K. Similä
From the University of Helsinki, Helsinki; North Carelia Central Hospital, Joensuu; Tampere University Hospital, Tampere; Helsinki University Central Hospital, Helsinki; Turku City Hospital, Turku, Finland. Study partially funded by Pfizer. A.V. Heinonen, BSc(pharm), University of Helsinki; K.J. Aaltonen, PhD (pharm), University of Helsinki; J.T. Joensuu, MSc(pharm), University of Helsinki; J.P. Lähteenmäki, MD, North Carelia Central Hospital; M.I. Pertovaara, MD, PhD, Tampere University Hospital; M.K. Romu, MD, Helsinki University Central Hospital; H.E. Hirvonen, MD, Helsinki University Central Hospital; A.K. Similä, MD, Turku City Hospital; M.L. Blom, PhD, Professor, University of Helsinki; DC Nordström, MD, PhD, Adj. Professor, University of Helsinki, and Helsinki University Central Hospital. Address correspondence to A.V. Heinonen, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland. E-mail: arto.heinonen@helsinki.fi. Accepted for publication August 5, 2015.
Marja L. Blom
From the University of Helsinki, Helsinki; North Carelia Central Hospital, Joensuu; Tampere University Hospital, Tampere; Helsinki University Central Hospital, Helsinki; Turku City Hospital, Turku, Finland. Study partially funded by Pfizer. A.V. Heinonen, BSc(pharm), University of Helsinki; K.J. Aaltonen, PhD (pharm), University of Helsinki; J.T. Joensuu, MSc(pharm), University of Helsinki; J.P. Lähteenmäki, MD, North Carelia Central Hospital; M.I. Pertovaara, MD, PhD, Tampere University Hospital; M.K. Romu, MD, Helsinki University Central Hospital; H.E. Hirvonen, MD, Helsinki University Central Hospital; A.K. Similä, MD, Turku City Hospital; M.L. Blom, PhD, Professor, University of Helsinki; DC Nordström, MD, PhD, Adj. Professor, University of Helsinki, and Helsinki University Central Hospital. Address correspondence to A.V. Heinonen, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland. E-mail: arto.heinonen@helsinki.fi. Accepted for publication August 5, 2015.
Dan C. Nordström
From the University of Helsinki, Helsinki; North Carelia Central Hospital, Joensuu; Tampere University Hospital, Tampere; Helsinki University Central Hospital, Helsinki; Turku City Hospital, Turku, Finland. Study partially funded by Pfizer. A.V. Heinonen, BSc(pharm), University of Helsinki; K.J. Aaltonen, PhD (pharm), University of Helsinki; J.T. Joensuu, MSc(pharm), University of Helsinki; J.P. Lähteenmäki, MD, North Carelia Central Hospital; M.I. Pertovaara, MD, PhD, Tampere University Hospital; M.K. Romu, MD, Helsinki University Central Hospital; H.E. Hirvonen, MD, Helsinki University Central Hospital; A.K. Similä, MD, Turku City Hospital; M.L. Blom, PhD, Professor, University of Helsinki; DC Nordström, MD, PhD, Adj. Professor, University of Helsinki, and Helsinki University Central Hospital. Address correspondence to A.V. Heinonen, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland. E-mail: arto.heinonen@helsinki.fi. Accepted for publication August 5, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study
Arto V. Heinonen, Kalle J. Aaltonen, Jaana T. Joensuu, Jukka P. Lähteenmäki, Marja I. Pertovaara, Matti K. Romu, Hanna E. Hirvonen, Aki K. Similä, Marja L. Blom, Dan C. Nordström
The Journal of Rheumatology Oct 2015, jrheum.150389; DOI: 10.3899/jrheum.150389
Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study
Arto V. Heinonen, Kalle J. Aaltonen, Jaana T. Joensuu, Jukka P. Lähteenmäki, Marja I. Pertovaara, Matti K. Romu, Hanna E. Hirvonen, Aki K. Similä, Marja L. Blom, Dan C. Nordström
The Journal of Rheumatology Oct 2015, jrheum.150389; DOI: 10.3899/jrheum.150389